Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRAF V600E PTEN del |
Therapy | Dabrafenib + Neratinib + Trametinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PTEN del | melanoma | sensitive | Dabrafenib + Neratinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Nerlynx (neratinib) restored sensitivity to Tafinlar (dabrafenib) and Mekinist (trametinib) and led to synergistic inhibition of a melanoma cell line harboring BRAF V600E and engineered via CRISPR-Cas9 to harbor a PTEN knockout in culture (PMID: 38854737). | 38854737 |
PubMed Id | Reference Title | Details |
---|---|---|
(38854737) | Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition. | Full reference... |